WO1994017773A3 - Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 - Google Patents

Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 Download PDF

Info

Publication number
WO1994017773A3
WO1994017773A3 PCT/EP1994/000283 EP9400283W WO9417773A3 WO 1994017773 A3 WO1994017773 A3 WO 1994017773A3 EP 9400283 W EP9400283 W EP 9400283W WO 9417773 A3 WO9417773 A3 WO 9417773A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
agonist
analog
pharmaceutical composition
effective amount
Prior art date
Application number
PCT/EP1994/000283
Other languages
French (fr)
Other versions
WO1994017773A2 (en
Inventor
Michel Goldman
Thierry Velu
Daniel Abramowicz
Catherine Bruyns
Paul Capel
Anne Delvaux
Vincent Donckier
Catherine Gerard
Arnaud Marchant
Olivier Pradier
Liliane Schandene
Fabienne Willems
Original Assignee
Michel Goldman
Thierry Velu
Daniel Abramowicz
Catherine Bruyns
Paul Capel
Anne Delvaux
Vincent Donckier
Catherine Gerard
Arnaud Marchant
Olivier Pradier
Liliane Schandene
Fabienne Willems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel Goldman, Thierry Velu, Daniel Abramowicz, Catherine Bruyns, Paul Capel, Anne Delvaux, Vincent Donckier, Catherine Gerard, Arnaud Marchant, Olivier Pradier, Liliane Schandene, Fabienne Willems filed Critical Michel Goldman
Priority to EP94906191A priority Critical patent/EP0681589A1/en
Priority to JP6517615A priority patent/JPH08510719A/en
Priority to AU60008/94A priority patent/AU6000894A/en
Publication of WO1994017773A2 publication Critical patent/WO1994017773A2/en
Publication of WO1994017773A3 publication Critical patent/WO1994017773A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention relates to a use of Interleukin-10 (IL-10) or analogs or agonists thereof, for the manufacture of a medicament for the treatment or prevention of diseases involving: i) Interleukin-5 production by T-lymphocytes, or; ii) activation of T-lymphocytes through the B7/CD28 or ICAM-1/LFA-1 pathway, or; iii) activation of the procoagulant activity of monocytes; iv) severe infectious diseases involving Tumour Necrosis Factor (TNF).
PCT/EP1994/000283 1993-02-01 1994-02-01 Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 WO1994017773A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94906191A EP0681589A1 (en) 1993-02-01 1994-02-01 Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
JP6517615A JPH08510719A (en) 1993-02-01 1994-02-01 Use of a pharmaceutical composition containing an effective amount of interleukin-10, its analogs and / or agonists
AU60008/94A AU6000894A (en) 1993-02-01 1994-02-01 Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93400242.9 1993-02-01
EP93400242 1993-02-01

Publications (2)

Publication Number Publication Date
WO1994017773A2 WO1994017773A2 (en) 1994-08-18
WO1994017773A3 true WO1994017773A3 (en) 1994-12-22

Family

ID=8214672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/000283 WO1994017773A2 (en) 1993-02-01 1994-02-01 Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10

Country Status (5)

Country Link
EP (1) EP0681589A1 (en)
JP (1) JPH08510719A (en)
AU (1) AU6000894A (en)
CA (1) CA2155109A1 (en)
WO (1) WO1994017773A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
JPH11510806A (en) * 1995-08-09 1999-09-21 シェーリング コーポレイション Combination of interleukin 10 and cyclosporin for immunosuppressive treatment
WO1998026066A1 (en) * 1996-12-09 1998-06-18 Ariad Gene Therapeutics, Inc. Expression of proteins for treating asthma via ligand mediated activation of their encoding genes
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20060127357A1 (en) * 2002-11-29 2006-06-15 Roncarolo Maria G Rapamycin and il-10 for the treatment of immune diseases
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
RU2538613C2 (en) * 2012-10-11 2015-01-10 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук Interleukin-10, using it and based composition for treating brain neurodegenerative processes
EP2986306A4 (en) * 2013-04-18 2016-12-07 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20160079114A (en) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (en) 2014-10-22 2017-11-13 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders.
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (en) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 PEGylated interleukin-10 for cancer treatment
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367596A1 (en) * 1988-11-03 1990-05-09 Schering Corporation Antagonist to interleukin-5 for preventing or reducing eosinophilia
WO1991000349A1 (en) * 1989-06-28 1991-01-10 Schering Corporation Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same
WO1993000920A1 (en) * 1991-07-04 1993-01-21 Schering Aktiengesellschaft Berlin Und Bergkamen Use of interleukine 10 to produce drugs with a tumour-inhibiting action
EP0541214A2 (en) * 1991-08-06 1993-05-12 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
WO1993017698A1 (en) * 1992-03-04 1993-09-16 Schering Corporation Use of interleukin-10 to suppress graft-vs.-host disease
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
WO1994004180A2 (en) * 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367596A1 (en) * 1988-11-03 1990-05-09 Schering Corporation Antagonist to interleukin-5 for preventing or reducing eosinophilia
WO1991000349A1 (en) * 1989-06-28 1991-01-10 Schering Corporation Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same
WO1993000920A1 (en) * 1991-07-04 1993-01-21 Schering Aktiengesellschaft Berlin Und Bergkamen Use of interleukine 10 to produce drugs with a tumour-inhibiting action
EP0541214A2 (en) * 1991-08-06 1993-05-12 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
WO1993017698A1 (en) * 1992-03-04 1993-09-16 Schering Corporation Use of interleukin-10 to suppress graft-vs.-host disease
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
WO1994004180A2 (en) * 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CATHERINE GERARD ET AL: "interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, February 1993 (1993-02-01), NEW YORK, pages 547 - 550 *
DAVID F. FIORENTINO ET AL: "IL-10 inhibits cytokine production by activated macrophages", JOURNAL OF IMMUNOLOGY, vol. 147, no. 11, 1991, BALTIMORE, pages 3815 - 3822 *
DEL PETRE, G. ET AL: "Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production", JOURNAL OF IMMUNOLOGY., vol. 150, no. 2, 15 January 1993 (1993-01-15), BALTIMORE US, pages 353 - 360 *
H. SPITS ET AL: "Functional characterization of human IL-10", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 99, 1992, NEW YORK, pages 8 - 15 *
HOWARD, M. ET AL: "Biological properties of Interleukin 10", IMMUNOLOGY TODAY, vol. 13, no. 6, 1992, CAMBRIDGE, U.K., pages 198 - 200 *
MARIA-TERESA BEJARANO ET AL: "Interleukin 10 inhibits allogenic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures", INTERNATIONAL IMMUNOLOGY, vol. 4, no. 12, 1992, OXFORD, pages 1389 - 1397 *
PRADIER O. ET AL: "Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, 1993, WEINHEIM, pages 2700 - 2703 *
ROBERT BERKOW: "THE MERK MANUAL OF DIAGNOSIS AND THERAPY", 1992, MERCK RESEARCH LABORATORIES, RAHWAY, N.J. *

Also Published As

Publication number Publication date
JPH08510719A (en) 1996-11-12
AU6000894A (en) 1994-08-29
CA2155109A1 (en) 1994-08-18
EP0681589A1 (en) 1995-11-15
WO1994017773A2 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
WO1994017773A3 (en) Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
UA34428C2 (en) Substituted phenylimidazolidines, process for preparation thereof, pharmaceutical composition, intermediates
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
ES2091727A1 (en) Insulin analog formulations
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
BG108927A (en) INHIBITORS OF INTERLEUKIN-1'beta' CONVERTING ENZYME, METHOD FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THE USE AS A MEDICAMENTOUS FORM THEREOF
CA2117265A1 (en) Enhanced Skin Penetration System for Improved Topical Delivery of Drugs
AU3502289A (en) Method for administering the drug deprenyl so as to minimize the danger of side effects
EP0625991A4 (en) Improved alpha interferon composition and method for its production from human peripheral blood leukocytes.
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
DE69940557D1 (en) A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER
IL112111A0 (en) Peptide derivatives and pharmaceutical compositions containing them
ATE44130T1 (en) PHARMACEUTICAL PRODUCTS CONTAINING MAGNESIUM TRISILICATE ADSORBENT WITH MEDICINAL ACTIVE SUBSTANCE ADsorbed ONTO IT.
IL102734A0 (en) Tissue-selective insulin analogs,their production and pharmaceutical compositions containing them
HUT43494A (en) Process for producing pharmaceutical composition containing interferone-alpha
EP1026157A3 (en) Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
TW336172B (en) Pharmaceutical compositions of interleukin-10 (IL-10) to prevent insulin-dependent diabetes mellitus
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
EP0363083A3 (en) Pharmaceutical preparation for treatment of thrombocytopenic or platelet function-deficient disease
ES8801682A1 (en) Polyprenyl compounds, processes for preparing them, and pharmaceutical composition containing them.
AU4361996A (en) The use of inositoltrisphosphate for the preparing of medicaments
AU3499389A (en) Compounds with central analgesic activity, process for their preparation and pharmaceutical compositions containing them
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CN CZ FI GE HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CN CZ FI GE HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2155109

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994906191

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 495678

Country of ref document: US

Date of ref document: 19951013

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994906191

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994906191

Country of ref document: EP